Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.

UNLABELLED: We compared the efficacies of (18)F-FDG PET and (99m)Tc-bone scintigraphy for the detection of bone metastases in patients with differentiated thyroid carcinoma (DTC). METHODS: We examined 47 patients (32 women, 15 men; mean age +/- SD, 57.0 +/- 10.7 y) with DTC who had undergone total thyroidectomy and were hospitalized to be given (131)I therapy. All patients underwent both whole-body (18)F-FDG PET and (99m)Tc-bone scintigraphy. The skeletal system was classified into 11 anatomic segments and assessed for the presence of bone metastases. Bone metastases were verified either when positive findings were obtained on >2 imaging modalities--(201)Tl scintigraphy, (131)I scintigraphy, and CT--or when MRI findings were positive if vertebral MRI was performed. RESULTS: Bone metastases were confirmed in 59 of 517 (11%) segments in 18 (38%) of the 47 study patients. The sensitivities (visualization rate) for bone metastases on a segment basis using (18)F-FDG PET and (99m)Tc-bone scintigraphy were 50 of 59 (84.7%) and 46 of 59 (78.0%), respectively; the difference between these values was not statistically significant. There were only 2 (0.4%) false-positive cases in a total of 451 bone segments without bone metastases when examined by (18)F-FDG PET, whereas 39 (8.6%) were false-positive when examined by (99m)Tc-bone scintigraphy. Therefore, the specificities of (18)F-FDG PET and (99m)Tc-bone scintigraphy were 449 of 451 (99.6%) and 412 of 451 (91.4%), respectively; the difference between these values was statistically significant (P < 0.001). The overall accuracies of (18)F-FDG PET and (99m)Tc-bone scintigraphy were 499 of 510 (97.8%) and 458 of 510 (89.8%), respectively; the difference between these was also statistically significant (P < 0.001). CONCLUSION: The specificity and the overall accuracy of (18)F-FDG PET for the diagnosis of bone metastases in patients with DTC are higher than those of (99m)Tc-bone scintigraphy, whereas the difference in the sensitivities of both modalities is not statistically significant. In comparison with (99m)Tc-bone scintigraphy, (18)F-FDG PET is superior because of its lower incidence of false-positive results in the detection of bone metastases of DTC.

Cerebral glucose metabolism change in patients with complex regional pain syndrome: a PET study.

PURPOSE: The aim of this study was to examine abnormalities of the central nervous system in patients with chronic pain who were diagnosed with complex regional pain syndrome (CRPS). MATERIALS AND METHODS: Brain activity was assessed using (18)F-fluorodeoxyglucose positron emission tomography. The data collected from 18 patients were compared with data obtained from 13 normal age-matched controls. RESULTS: Our results showed that glucose metabolism was bilaterally increased in the secondary somatosensory cortex, mid-anterior cingulated cortex (ACC) or posterior cingulated cortex (PCC) (or both), parietal cortex, posterior parietal cortex (PPC), and cerebellum as well as in the right posterior insula and right thalamus in our patients. In contrast, glucose metabolism was reduced contralaterally in the dorsal prefrontal cortex and primary motor cortex. Glucose metabolism was bilaterally elevated in the mid-ACC/PCC and the PPC, which correlated with pain duration. CONCLUSION: These data suggested that glucose metabolism in the brains of patients with CRPS changes dramatically at each location. In particular, glucose metabolism was increased in the areas concerned with somatosensory perception, possibly due to continuous painful stimulation.

Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT.

UNLABELLED: Earlier investigations showed that N-isopropyl-p-123I-iodoamphetamine SPECT (123I-IMP SPECT) is useful for the diagnosis of uveal malignant melanoma, whereas the feasibility and usefulness of 18F-FDG PET in uveal malignant melanoma have not yet been established. We compared the usefulness of 123I-IMP SPECT and 18F-FDG PET for the detection of uveal malignant melanoma on the same subjects. METHODS: Nineteen patients (10 men, 9 women) with suspected uveal malignant melanoma were examined by 123I-IMP SPECT. Thirteen of them were also examined by 18F-FDG PET. 123I-IMP SPECT was performed at 15 min or at 3 and 24 h after intravenous administration of 123I-IMP. RESULTS: In 12 of 19 study patients, 123I-IMP SPECT obtained at 24 h after intravenous administration of 123I-IMP delineated an area of increased uptake in the site corresponding to the ocular tumor. All of the ocular tumors in the 12 123I-IMP SPECT-positive patients were confirmed histopathologically and clinically to be uveal malignant melanoma. The other 7 123I-IMP-SPECT-negative patients have been monitored under the diagnosis of choroidal nevus, choroidal hemangioma, hyperplasia of the pigment epithelium of the retina, or idiopathic inflammatory lesions without any complications. In a total of 13 patients examined by 18F-FDG PET, 9 of whom were 123I-IMP SPECT positive and 4 were negative, only 1 patient showed abnormal uptake of 18F-FDG PET in the site corresponding to the ocular tumor. Therefore, 8 of 9 patients with uveal malignant melanoma showed false-negative results in 18F-FDG PET. The 18F-FDG PET-positive patient with uveal malignant melanoma had the largest tumor mass with a short diameter of 12 mm, a long diameter of 17 mm, and a height of 7 mm. In the other 8 18F-FDG PET-negative patients, the tumors had a dimension of 11 x 13 x 7 mm or less. CONCLUSION: 123I-IMP SPECT is a sensitive and accurate method for the detection of uveal malignant melanoma, whereas the efficacy of 18F-FDG PET for this purpose is low because of a high incidence of false-negative results. 123I-IMP SPECT is far more superior in comparison with 18F-FDG PET in detecting uveal malignant melanoma.

[Examination of SUV of regional activity concentration for simultaneous emission/transmission acquisition using the mask technique].

To achieve quantitative accuracy of simultaneous emission/transmission (SET) acquisition using the mask technique, we determined the factor of expression that derives the true transmission data from the measured transmission and emission data. We then evaluated the standardized uptake value (SUV) of the regional activity concentration derived respectively from the SET scans and conventional scans. First, to determine the attenuation factor for the transmission source when the photons of the cylindrical phantom filled with (18)F solution reached emission memory, SET scans were performed with a dummy transmission source and under the blank status of the transmission source. Second, to evaluate the SUV, we used a hollow-sphere phantom filled with (18)F solution whose activity concentrations were approximately 3 and 5 times that of the background. Then we performed conventional and SET scans of the phantom for solutions ranging from the higher concentration to the lower concentration. All of the data were reconstructed with the decay correction, and the SUV of each sphere was derived. The results demonstrated that, when the conventional factor was used, SUV was underestimated according to the increasing activity concentration of the solution. However, when a new factor that took into account the attenuation of the transmission source was used, there was no significant difference in the SUV. We estimated the SUV derived from the SET scans was within 3% for the large spheres and within 16% for the small spheres.